Cambridge TV on Twitter: "At 21:00 Dr Mark Toshner of @PapworthHosp and Dr Matthew Hallsworth of @OfficialNIHR talk PAH treatments @NIHR_NOCRI https://t.co/ME8feZjtsg" / Twitter
Dr Mark Toshner, Author at The Spectator
Cambridge team develop test that can diagnose Covid-19 in less than 90 minutes | ITV News Anglia
The severe allergy rates in vaccinations are one in a million, we're just being cautious at the moment.' Reassurance from Dr Mark Toshner from Royal... | By ITV Anglia | Facebook
What you need to know about new PAH therapy sotatercept - YouTube
Mark Toshner
Mark Toshner (@mark_toshner) / Twitter
NIHR Cambridge CRF | | Dr Estee Török on tackling Covid-19
Vaccine Q+A: Submit your video questions for our expert | ITV News Anglia
Toshner :: Royal Papworth Hospital
Heart and Lung Research Institute
Luke Daines | The University of Edinburgh
Paul Yu MD PhD on Twitter: "Enjoying a pint with Mark Toshner and Stefan Graf at the Eagle Pub in Cambridge after an exciting day of Cardiopulmonary science with @bwhcvls @Cambridge_Uni @Cambridgecardio
Dr Mark Toshner, honorary consultant at CUH explains more about the trial | hospital, clinical trial | An Addenbrooke's led study has enrolled a thousand patients hospitalised with Covid from across the
Dr. Mark Toshner is Chair of the Inspire Alpine® board but his day job has seen him involved in the AstraZeneca-Oxford Covid-19 Vaccine trial. 🦠 💉 In... | By Inspire Alpine | Facebook
Mark Toshner - Blogger Biography | Down To Earth
There isn't anything like it in the UK"
🎙️New podcast episode: Cambridge researchers Joe Newman and Dr Mark Toshner talk about an exciting new PH drug trial & explain why your thoughts on... | By Pulmonary Hypertension Association UK | Facebook
IL-6 in pulmonary hypertension: why novel is not always best
47 pictures as Heart and Lung Research Institute officially opens on Cambridge Biomedical Campus with ambitious target
COVID-19 vaccines and PH: The facts | PHA
1,000 Covid patients sign up to UK drug trial | CUH
Contact details - Cambridge Biomedical Research Centre
Royal Papworth Hospital NHS FT 💙 on Twitter: "“The safety bar for vaccine trials is incredibly high” Dr Mark Toshner is an honorary consultant at Royal Papworth Hospital and was the principal
Mark Toshner - Tocilizumab in the treatment of PAH: TRANSFORM-UK
We could all pay the price for the EU's foolish vaccine nationalism | The Spectator
Mark Toshner - Honorary Consultant Physician - Royal Papworth Hospital NHS Foundation Trust | LinkedIn
